pyridoxine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2836 65-23-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyridoxine
  • adermin
  • bezatin
  • pirivitol
  • pyridoxin
  • pyridoxine hydrochloride
  • pyridoxine (vit B6)
  • vitamin b6
  • pyridoxine HCl
The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990).
  • Molecular weight: 169.18
  • Formula: C8H11NO3
  • CLOGP: -0.35
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 73.58
  • ALOGS: -1.02
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.16 g O
0.16 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 222 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 39.43 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.66 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.98 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1993 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia aspiration 285.17 43.05 51 295 3691 2354048
Gastrooesophageal reflux disease 245.77 43.05 52 294 9043 2348696
Coma 240.19 43.05 51 295 9005 2348734
Somnolence 231.22 43.05 59 287 23426 2334313
Subileus 44.43 43.05 8 338 563 2357176
Maternal exposure during pregnancy 44.26 43.05 15 331 14848 2342891

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC A11HA02 ALIMENTARY TRACT AND METABOLISM
VITAMINS
OTHER PLAIN VITAMIN PREPARATIONS
Other plain vitamin preparations
ATC J04AM08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA EPC N0000192800 Vitamin B6 Analog
FDA Chemical/Ingredient N0000005657 Vitamin B 6
FDA Chemical/Ingredient N0000175452 Analogs/Derivatives
MeSH PA D018977 Micronutrients
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pregnancy, function indication 289908002
Vitamin B6 deficiency indication 386080007 DOID:8455
Breastfeeding (mother) indication 413712001
Drug-Induced Pyridoxine Deficiency indication
Pyridoxine-Dependent Seizure indication
Nutritional disorder contraindication 2492009 DOID:374
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Hyperkalemia contraindication 14140009
Gastroenteritis contraindication 25374005 DOID:2326
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Hemosiderosis contraindication 39011001 DOID:12119
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Gastrectomy contraindication 53442002
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Schizophrenia contraindication 58214004 DOID:5419
Acute nephropathy contraindication 58574008
Leber's optic atrophy contraindication 58610003 DOID:705
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Diarrhea contraindication 62315008
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by acetaminophen contraindication 70273001
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Atrophic gastritis contraindication 84568007 DOID:8929
Autoimmune disease contraindication 85828009
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Gastrointestinal obstruction contraindication 126765001
Acute hepatic failure contraindication 197270009
Impaired renal function disorder contraindication 197663003
Gastroparesis contraindication 235675006
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Esophageal dysmotility contraindication 266434009 DOID:9192
Diabetic - poor control contraindication 268519009
Peripheral nerve disease contraindication 302226006
Primary adrenocortical insufficiency contraindication 373662000
Diverticular disease contraindication 397881000
Hemochromatosis contraindication 399187006 DOID:2352
Ketoacidosis in diabetes mellitus contraindication 420422005 DOID:1837
Diabetic peripheral neuropathy contraindication 424736006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Chronic Hepatic Disease contraindication
Genitourinary Tract Infections contraindication
Repeated Blood Transfusions contraindication
Prolonged-Severe Nausea and Vomiting contraindication
Esophageal Compression contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.98 acidic
pKa2 13.8 acidic
pKa3 4.94 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG DICLEGIS DUCHESNAY N021876 April 8, 2013 RX TABLET, DELAYED RELEASE ORAL 6340695 June 21, 2021 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9089489 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9375404 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9526703 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9937132 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Phosphoserine aminotransferase Enzyme WOMBAT-PK
Cystathionine beta-synthase Enzyme WOMBAT-PK
Pyridoxal kinase Kinase WOMBAT-PK
Pyridoxal phosphate phosphatase Enzyme WOMBAT-PK
Pyridoxine-5'-phosphate oxidase Enzyme WOMBAT-PK
Serine hydroxymethyltransferase, cytosolic Enzyme WOMBAT-PK

External reference:

IDSource
4019922 VUID
N0000148007 NUI
C0034272 UMLSCUI
D02179 KEGG_DRUG
68Y4CF58BV UNII
58-56-0 SECONDARY_CAS_RN
767286000 SNOMEDCT_US
430469009 SNOMEDCT_US
4019922 VANDF
684879 RXNORM
6601 MMSL
d00412 MMSL
004538 NDDF
1054 PUBCHEM_CID
CHEBI:16709 CHEBI
CHEMBL1364 ChEMBL_ID
DB00165 DRUGBANK_ID
CHEMBL1200756 ChEMBL_ID
2216 INN_ID
D011736 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NataFort HUMAN PRESCRIPTION DRUG LABEL 10 0178-0716 TABLET 10 mg ORAL Unapproved drug other 12 sections
CitraNatal Harmony 3.0 HUMAN PRESCRIPTION DRUG LABEL 7 0178-0796 CAPSULE, GELATIN COATED 25 mg ORAL unapproved drug other 10 sections
CitraNatal Harmony HUMAN PRESCRIPTION DRUG LABEL 8 0178-0798 CAPSULE, GELATIN COATED 25 mg ORAL UNAPPROVED DRUG OTHER 12 sections
CitraNatal Harmony HUMAN PRESCRIPTION DRUG LABEL 8 0178-0799 CAPSULE, GELATIN COATED 25 mg ORAL Unapproved drug other 11 sections
CitraNatal Harmony HUMAN PRESCRIPTION DRUG LABEL 8 0178-0812 CAPSULE, GELATIN COATED 25 mg ORAL Unapproved drug other 11 sections
CitraNatal 90 DHA HUMAN PRESCRIPTION DRUG LABEL 13 0178-0821 TABLET 20 mg ORAL unapproved drug other 10 sections
CitraNatal 90 DHA HUMAN OTC DRUG LABEL 10 0178-0829 TABLET 20 mg ORAL Unapproved drug other 10 sections
CITRANATAL B-CALM HUMAN PRESCRIPTION DRUG LABEL 6 0178-0832 KIT 25 mg None unapproved drug other 11 sections
CITRANATAL B-CALM HUMAN PRESCRIPTION DRUG LABEL 6 0178-0832 KIT 25 mg None unapproved drug other 11 sections
CitraNatal Rx HUMAN PRESCRIPTION DRUG LABEL 11 0178-0858 TABLET 20 mg ORAL Unapproved drug other 11 sections
CitraNatal Rx HUMAN PRESCRIPTION DRUG LABEL 12 0178-0859 TABLET 20 mg ORAL Unapproved drug other 8 sections
CitraNatal HUMAN PRESCRIPTION DRUG LABEL 7 0178-0866 KIT 25 mg None Unapproved drug other 11 sections
CitraNatal HUMAN PRESCRIPTION DRUG LABEL 7 0178-0866 KIT 25 mg None Unapproved drug other 11 sections
CitraNatal Assure HUMAN PRESCRIPTION DRUG LABEL 13 0178-0891 KIT 25 mg None unapproved drug other 12 sections
CitraNatal Assure HUMAN PRESCRIPTION DRUG LABEL 14 0178-0893 KIT 25 mg None Unapproved drug other 12 sections
CitraNatal DHA HUMAN PRESCRIPTION DRUG LABEL 14 0178-0894 KIT 20 mg None unapproved drug other 11 sections
CitraNatal Medley HUMAN PRESCRIPTION DRUG LABEL 7 0178-0896 CAPSULE, GELATIN COATED 12.50 mg ORAL unapproved drug other 9 sections
CitraNatal DHA HUMAN OTC DRUG LABEL 12 0178-0898 TABLET 20 mg ORAL Unapproved drug other 10 sections
Doxylamine succinate and pyridoxine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0591-2132 TABLET, DELAYED RELEASE 10 mg ORAL ANDA 18 sections
Multi-Vit with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 0603-1449 SOLUTION 0.40 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Multi-Vit with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 0603-1450 SOLUTION 0.40 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Multi-Vit with Fluoride and Iron HUMAN PRESCRIPTION DRUG LABEL 10 0603-1452 SOLUTION 0.40 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Folbic HUMAN PRESCRIPTION DRUG LABEL 3 0615-7575 TABLET 25 mg ORAL UNAPPROVED DRUG OTHER 10 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 11 0642-0070 CAPSULE, GELATIN COATED 2.50 mg ORAL unapproved drug other 6 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 9 0642-0072 CAPSULE 15 mg ORAL UNAPPROVED DRUG OTHER 9 sections
Select-OB Plus DHA HUMAN PRESCRIPTION DRUG LABEL 15 0642-0075 KIT 2.50 mg None Unapproved drug other 10 sections
Vitafol-OB Plus DHA HUMAN PRESCRIPTION DRUG LABEL 10 0642-0076 KIT 2.50 mg None Unapproved drug other 13 sections
Select OB HUMAN PRESCRIPTION DRUG LABEL 11 0642-0077 TABLET, CHEWABLE 2.50 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Vitafol OB HUMAN PRESCRIPTION DRUG LABEL 9 0642-0079 TABLET 2.50 mg ORAL Unapproved drug other 11 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 12 0642-0092 CAPSULE, LIQUID FILLED 2.50 mg ORAL UNAPPROVED DRUG OTHER 10 sections